Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.64 |
| ▸ | EGFR | P00533 | 12/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.49 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11910290 | 1.00 | MRGPRX4 (0.64) | MRGPRX4EGFRERBB2KDM4EGAA | |
| SCHEMBL24388658 | 0.85 | CYP1A2 (0.61) | EGFRERBB2GAKMAOB | |
| SCHEMBL12864874 | 0.85 | MAOB (0.56) | MRGPRX4EGFRERBB2KDM4EGAA | |
| SCHEMBL12524900 | 0.85 | MRGPRX4 (0.62) | MRGPRX4KDM4EGAAMAOB | |
| SCHEMBL12824288 | 0.85 | MRGPRX4 (0.67) | MRGPRX4KDM4EMAOB | |
| SCHEMBL11960847 | 0.84 | EGFR (0.56) | MRGPRX4EGFRERBB2KDM4EGAA | |
| SCHEMBL29826082 | 0.84 | MRGPRX4 (0.65) | MRGPRX4MAOB | |
| SCHEMBL22874527 | 0.84 | EGFR (0.55) | MRGPRX4EGFRERBB2KDM4EGAA | |
| SCHEMBL25648997 | 0.84 | EGFR (0.55) | MRGPRX4EGFRERBB2GAKMAOB | |
| SCHEMBL17858626 | 0.83 | MRGPRX4 (0.53) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121300-A1 | METHOD OF FLUORINATION USING IODONIUM YLIDES | THE GENERAL HOSPITAL CORPORATION | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121300-A1 | METHOD OF FLUORINATION USING IODONIUM YLIDES | FLI1, ABL1, PFAS | MRGPRX4 1405/4885EGFR 635/4885ERBB2 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.